EKF Diagnostics Holdings plc (AIM:EKF)

London flag London · Delayed Price · Currency is GBP · Price in GBX
27.00
+0.55 (2.08%)
Jun 6, 2025, 4:37 PM GMT+1
-15.09%
Market Cap 118.79M
Revenue (ttm) 50.19M
Net Income (ttm) 6.24M
Shares Out 449.09M
EPS (ttm) 0.01
PE Ratio 19.23
Forward PE 18.15
Dividend n/a
Ex-Dividend Date n/a
Volume 197,104
Average Volume 542,362
Open 25.80
Previous Close 26.45
Day's Range 25.80 - 27.00
52-Week Range 18.40 - 32.90
Beta 0.24
RSI 63.03
Earnings Date Jun 17, 2025

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1990
Employees 303
Stock Exchange London Stock Exchange AIM
Ticker Symbol EKF
Full Company Profile

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.

Financial Statements

News

There is no news available yet.